Opsona Therapeutics appoints new VP of Research
Opsona Therapeutics (Dublin, Ireland) has today announced it has recruited Dr Andrew Parker as its new Vice-President of Research. Dr Parker joins Opsona with 10 years drug discovery experience from AstraZeneca, where he held the responsibility for a group of over 30 researchers identifying compounds for inflammatory diseases such as rheumatoid arthritis, osteoarthritis and COPD. Prior to this he was at the Johnson & Johnson Pharmaceutical Research Institute of Janssen Pharmaceutica in Belgium.
“Andrew has a considerable amount of experience in the discovery of new compounds in the field of autoimmune and inflammatory diseases”, says Mark Heffernan, Opsona’s CEO. “His expertise complements our current programmes and his vision will drive the future discovery efforts of the company”.
Opsona is a drug development company, focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases. The company was founded in 2004 with three of Trinity College Dublin’s respected Immunologists. The company is specifically interested drugs which modulate the innate immune system and its signalling, specifically Toll-Like Receptors (TLR). Opsona has a pipeline of
therapeutics in advanced pre-clinical development which modulate the innate immune system, including biologics, peptides and small molecules. The company has signed some significant partnering and collaborative deals, such as with Wyeth (USA).
The company is based at the Ashford House (Second Floor), Tara Street, Dublin and has laboratories in Lausanne, Switzerland.